Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1991-09-12
1993-04-20
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514867, A61K 31495, A61K 3150
Patent
active
052043479
ABSTRACT:
A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals containing 1 to 4 carbon atoms, R.sub.2 and R.sub.3 are independently selected from the group consisting of H, oxo, and alkyl radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow
REFERENCES:
patent: 3890319 (1975-07-01), Danielwicz et al.
Gellai et al, Renal Effects of Selective Alpha-1 and Alpha-2 Adrenoceptor Agonists in Conscious, Normotensive Rats, Journal of Pharmcol & Experimental Therapeutics, 240, p. 723 (1987).
Fondacaro et al, Selective Alpha-2 Adrenoceptor Agonists Alter Fluid and Electrolyte Transport in Mammalian Small Intestine, Journal of Pharmcol. & Experimental Therapeutics, 247, p. 481 (1988).
Burke et al, Ocular Effects of A Relatively Selective Alpha-2 agonists (UK-14,304-18) in Cats, Rabbits and Monkeys, Current Eye Research, 5, p. 665 (1986).
Jumblatt et al, Alpha-2 adrenergic modulation of norepinephgrine secretion in the perfused rabbit iris-ciliary body, Curretn Eye Research, 6, p. 767 (1987).
Mittag, Ph.D., Ocular Effects of Selective Alpha-Adrenergic Agents: A New Drug Paradox?, Annals of Ophthalmology, p. 201, (Mar. 1983).
Gellai et al, Mechanism of Alpha-2-adrenoceptor agonist-induced diuresis, American Journal Physiology, p. F317, (1988).
Timmermans et al, Clonidine and some bridge analogues; cardiovascular effects and nuclear magnetic resonance data (H/C), Eur. J. Med. Chem. 15, p. 323 (1980).
Isom et al, Alpha-2-Adrenergic Receptors Accelerate Na/H Exchange in Neuroblastoma X Glioma Cells, J. Biol. Chem., 262, p. 6750 (1987).
Fielding et al, Clonidine: New Research on Psychotropic Drug Pharmacology from Medicinal Research Revers, vol. 1, pp. 97-123 (1981).
Jarrott, Clonidine and related compounds from Handbook of Hypertension, vol. 5, p. 113 (1984).
Dharmsathaphorn, Alpha-2-Adrenergic Agonists: A New Class of Antidiarrheal Drug Gastroenterology 1987; 91:796-775.
Allergan Inc.
Jordan Kimberly R.
Uxa, Jr. Frank J.
Waddell Frederick E.
LandOfFree
Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxaline does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxaline, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxaline will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1526287